AC Immune (ACIU) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• AC Immune is anticipated to reveal its Q2 2025 earnings results on August 5th, projecting earnings of ($0.18) per share and revenue of $1.98 million.
• AC Immune's last reported earnings reflected a negative net margin of 177.79% and a revenue of $1.12 million, compared to analyst expectations of $1.99 million.
• The stock has shown significant movement, currently priced at $2.37, with a recent price target adjustment from equity analysts ranging from $12.00 to a downgrade at $16.00.

AC Immune (NASDAQ:ACIU - Get Free Report) will likely be releasing its Q2 2025 earnings data before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.18) per share and revenue of $1.98 million for the quarter.

AC Immune (NASDAQ:ACIU - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.01. AC Immune had a negative net margin of 177.79% and a negative return on equity of 44.60%. The business had revenue of $1.12 million during the quarter, compared to analyst estimates of $1.99 million. On average, analysts expect AC Immune to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AC Immune Price Performance

NASDAQ:ACIU traded down $0.04 during midday trading on Friday, hitting $2.12. The company's stock had a trading volume of 88,622 shares, compared to its average volume of 159,779. The firm has a market cap of $212.87 million, a P/E ratio of -3.66 and a beta of 1.62. AC Immune has a fifty-two week low of $1.43 and a fifty-two week high of $3.98. The firm's 50 day moving average is $2.00 and its 200-day moving average is $2.09.

Hedge Funds Weigh In On AC Immune

An institutional investor recently raised its position in AC Immune stock. Acadian Asset Management LLC grew its stake in AC Immune (NASDAQ:ACIU - Free Report) by 87.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 371,177 shares of the company's stock after purchasing an additional 172,796 shares during the period. Acadian Asset Management LLC owned approximately 0.37% of AC Immune worth $679,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 51.36% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. HC Wainwright dropped their target price on AC Immune from $16.00 to $12.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Wall Street Zen upgraded AC Immune from a "hold" rating to a "buy" rating in a research note on Tuesday, May 13th.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.